Industry Reports
Adocia announces financial results for 2013
Adocia announces today its annual financial results for 2013. The financial statements were approved by the board of directors on March 21, 2014 and will be submitted to the shareholders for approval during the next general meeting on June...
Industry Reports
Adocia: annual revenue of EUR 5.6 M in 2013
Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic molecules, in particular proteins and oncologic drugs, announces today its revenue for the last quarter 2013 and full year end. ...
Industry Reports
Bristol-Myers Squibb Reports fourth quarter and full year 2013 financial results
Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful...
Industry Reports
SurModics to Webcast First Quarter 2014 Earnings Conference Call on January 30
SurModics Inc. a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry announced today that it will host a live webcast of its first quarter 2014 conference call on Thursday January 30 at 4:00...
Industry Reports
RBI seeks clarity on FII investment in pharmaceutical sector
The Reserve Bank of India (RBI) has sought clarity on whether foreign portfolio investments can be allowed in existing companies without government approval, putting the spotlight back on a sector that has been the subject of much debate and...
Industry Reports
Medtech companies prepare for an innovation makeover
A report by PricewaterhouseCoopers For decades, the medtech industry was on the forefront of innovation, but now return on innovation investment is declining. Growth through technology innovation has slowed substantially and the benefits from incremental improvements to existing devices...
Industry Reports
Bristol-Myers Squibb reports third quarter 2013 financial results
Bristol-Myers Squibb Company has reported results for the third quarter of 2013 highlighted by the strong performance of key marketed products such as Yervoy, Orencia and Sprycel, the presentation of important clinical data for its immuno-oncology pipeline, and the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
